September 21, 2021
Welcome to hubXchange’s West Coast Immuno-Oncology Xchange 2021, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of highly-interactive roundtable discussions.
Discussion topics will cover Immune Biomarkers & Translational Research, Preclinical Research, Clinical Development, Cell Therapies and Next-Generation Therapies.
Take advantage of this unique and productive meeting format designed for maximum engagement, collaboration and networking with your peers.
Immune Biomarkers & Translational Research
Opening Address & Keynote Presentation: Uncovering the Complexities of TiME in a Digital Era
Vice President, Medical Director
Keith is a board-certified human anatomic pathologist leading Ultivue’s Pathology and Biomarker Analytics team, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine.
- What is the evidence that early tumor marker data are predictive of positive outcomes in patients?
- How are we leveraging early markers such as tumor size, tumor burden, circulating tumor DNA (ctDNA), NLR, etc.
- What quantitative and modeling approaches can help us leverage available data – eg. RWD, clinical trials database etc.
- Can AI/ML be applied to leverage which patients are likely to respond using Morpho-genomic analyses?
Novel biomarkers strategies to illuminate insights into the TME
- Exploring the dynamic nature of the TME
The need for new biomarker discovery and development
- Harnessing the ability to derive more meaningful information from precious tissue samples
- Novel strategies for advanced image analysis
Vice President, Vice President, Digital Health Strategies
Florian Leiss is VP Digital Health Strategies at Ultivue. He is responsible for digital and data-driven offerings and image analysis. Florian has been working for the 10+ years in software development for healthcare to make AI-powered CDx in oncology a reality, to support radiologists with routine reporting, or to empower pathologists with image analysis at AstraZeneca, Smart Reporting and Definiens. He holds PhDs in neuroscience and philosophy.
Senior Vice President, Marketing & Corporate Strategy
Brad Nelson has twenty five years of experience in leading rapid growth life science organizations, delivering new technology and applications for drug discovery, development and clinical markets. Working closely with leading pharmaceutical and biotech companies at Velocity11 (acquired by Agilent), Labcyte (acquired by Danaher), and Ionpath, Brad’s focus has been to deliver technologies that continually advance biopharmaceutical development.
- Discuss the current challenges and key considerations to be taken when designing assays to identify new
biomarkers in pan tumor applications.
- Examine the importance of biomarker quantification when phenotyping multiple targets across cell types.
- Explore how novel tissue staining technologies can be applied to interrogate new drug targets and
immune cell while preserving tissue architecture for spatial analysis.
Vice President of Research & Applications
Joseph Krueger serves as the scientific leader for Invicro’s Advanced Pathology Services and is responsible for developing new biomarker applications to meet drug development needs. Furthermore, he provides scientific expertise needed to support sponsor-based projects across therapeutic areas. Prior to joining Invicro, Joseph was Chief Scientific Officer at Flagship Biosciences where he led the R&D and Scientific efforts in applying novel quantitative tissue image analysis approaches to immuno-oncology and rare diseases to support drug and companion diagnostic development. Prior to Flagship Biosciences, he served in senior scientific roles in oncology drug development for OSI Pharmaceuticals and Pfizer.
Chief Medical Officer
Kenneth Bloom serves as the Chief Medical Officer for Advanced Pathology and Genomic Services at Invicro and Ambry Genetics, both Konica Minolta precision medicine companies. Kenneth brings more than 30 years of clinical and business experience in pathology, oncology, telemedicine, and bioinformatics. His role at Konica Minolta is to expand, strengthen and commercialize the full-suite of precision medicine capabilities offered within the pathology and genomics markets. Prior to joining Invicro, Kenneth held leadership positions within oncology at Human Longevity and GE Healthcare. He has also held faculty positions in clinical pathology at USC and Rush Medical Center.
3:10 – 3:40pm
- What are the next promising immune checkpoint pathways?
- What is the best strategy to target multiple immune checkpoint pathways?
- How to identify biomarkers to predict response to immune checkpoint blockade?
Director, Clinical Biomarkers
Yu Liang is currently Director of Clinical Biomarkers at Compugen heading implementation of biomarkers in clinical trials to develop drugs targeting immune checkpoints. He brings in 20 years of expertise and leadership in precision medicine, including assay development in research and IVD, and application of genomic and genetic profiling for patient stratification. Before Compugen, he was Director of Translational Sciences in Oncology at Ipsen, leading translation of pre-clinical biomarkers into early phase clinical trials. Prior to Ipsen, he led development of clinical biomarker for drugs targeting amino acid metabolism at Calithera and managed the clinical biomarker portfolios of Ibrutinib for non-Hodgkin’s lymphomas at Pharmacyclics.